These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19924505)

  • 1. The effect of L-Dopa administration on pursuit ocular movements in suspected Parkinson's disease.
    Marino S; Lanzafame P; Sessa E; Bramanti A; Bramanti P
    Neurol Sci; 2010 Jun; 31(3):381-5. PubMed ID: 19924505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of pursuit ocular movements in Parkinson's disease by using a video-based eye tracking system.
    Marino S; Sessa E; Di Lorenzo G; Lanzafame P; Scullica G; Bramanti A; La Rosa F; Iannizzotto G; Bramanti P; Di Bella P
    Eur Neurol; 2007; 58(4):193-7. PubMed ID: 17827965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.
    Merello M; Gerschcovich ER; Ballesteros D; Cerquetti D
    Parkinsonism Relat Disord; 2011 Nov; 17(9):705-7. PubMed ID: 21784692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smooth pursuit during dose-related on-off fluctuations in Parkinson's disease.
    Sharpe JA; Fletcher WA; Lang AE; Zackon DH
    Neurology; 1987 Aug; 37(8):1389-92. PubMed ID: 3614666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of patient rated treatment response with measured improvement in Parkinson's disease.
    Davidson MB; McGhee DJ; Counsell CE
    J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):1001-5. PubMed ID: 22626942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching L-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson's Disease.
    Mostile G; Nicoletti A; Dibilio V; Luca A; Raciti L; Sciacca G; Cicero CE; Vasta R; Donzuso G; Contrafatto D; Zappia M
    Clin Neuropharmacol; 2017; 40(1):6-10. PubMed ID: 27879548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of white matter MRI hyper-intensities on acute l-dopa response in patients with Parkinson's disease.
    Arena JE; Cerquetti D; Rossi M; Chaves H; Rollan C; Dossi DE; Merello M
    Parkinsonism Relat Disord; 2016 Mar; 24():126-8. PubMed ID: 26823237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirror movements in Parkinson's disease: An under-appreciated clinical sign.
    Chatterjee P; Banerjee R; Choudhury S; Mondal B; Kulsum MU; Chatterjee K; Kumar H
    J Neurol Sci; 2016 Jul; 366():171-176. PubMed ID: 27288800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-dopa treatment increases oscillatory power in the motor cortex of Parkinson's disease patients.
    Cao C; Li D; Zhan S; Zhang C; Sun B; Litvak V
    Neuroimage Clin; 2020; 26():102255. PubMed ID: 32361482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
    Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
    Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test.
    Fabbri M; Coelho M; Guedes LC; Chendo I; Sousa C; Rosa MM; Abreu D; Costa N; Godinho C; Antonini A; Ferreira JJ
    Parkinsonism Relat Disord; 2017 Jun; 39():37-43. PubMed ID: 28389156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hand coordination as a quantitative measure of motor abnormality and therapeutic response in Parkinson's disease.
    Benice TS; Lou JS; Eaton R; Nutt J
    Clin Neurophysiol; 2007 Aug; 118(8):1776-84. PubMed ID: 17576094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression.
    Malek N; Kanavou S; Lawton MA; Pitz V; Grosset KA; Bajaj N; Barker RA; Ben-Shlomo Y; Burn DJ; Foltynie T; Hardy J; Williams NM; Wood N; Morris HR; Grosset DG;
    Parkinsonism Relat Disord; 2019 Aug; 65():55-61. PubMed ID: 31105012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
    Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
    Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.